IBS007125 

IBS007125 is a c-Maf inhibitor. IBS007125 does not alter the protein level or post-translational modification of c-Maf. IBS007125 inhibits some target genes of c-Maf (such as ITGB7 and CCR1). IBS007125 exerts anticancer effects on multiple myeloma expressing c-Maf. IBS007125 can be used for the research of multiple myeloma^[1].

IBS007125 inhibits c-Maf transcriptional activity in HEK293T cells, as measured by reduced Ccl8 promoter-driven luciferase activity^[1].
IBS007125 (18 h pre-incubation before LPS stimulation; 24 h LPS stimulation) selectively suppresses c-Maf-dependent cytokine (CCL8, IL-10) production without affecting c-Maf-independent TNFα production in LPS-stimulated BMDMs^[1].
IBS007125 (0-20 μM; 5 days) suppresses proliferation of c-Maf-expressing RPMI-8226 multiple myeloma cells in a dose-dependent manner but does not affect proliferation of c-Maf-negative U266 multiple myeloma cells^[1].
IBS007125 (10 μM; 2 days for c-Maf mRNA; 3 days for ITGB7 and CCR1 mRNA) modestly reduces c-Maf mRNA expression and significantly represses expression of the c-Maf target genes ITGB7 and CCR1 in RPMI-8226 multiple myeloma cells^[1].
IBS007125 (10 μM; 2 days) does not affect c-Maf protein levels or post-translational modifications (as indicated by unaltered molecular weight) in RPMI-8226 multiple myeloma cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

258.32

C₁₄H₁₈N₄O

2941099-67-6

O=C1NC2=C(C=CC=C2)N=C1C/C(C(C)(C)C)=N/N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Asano K, et al. Identification of small compounds that inhibit multiple myeloma proliferation by targeting c-Maf transcriptional activity. Biochem Biophys Res Commun. 2023;684:149135.  [Content Brief]